Abiopharma

Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Castle Biosciences - Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Cerus Corporation - Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook

Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full–Year 2025 Results

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference